Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update

Autolus Therapeutics plc (NASDAQ:AUTL) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 7,680,000 shares, an increase of 22.1% from the November 30th total of 6,290,000 shares. Based on an average daily volume of 1,750,000 shares, the days-to-cover ratio is presently 4.4 days.

Autolus Therapeutics Stock Performance

Shares of AUTL stock traded down $0.04 during mid-day trading on Friday, hitting $2.26. 1,720,520 shares of the stock traded hands, compared to its average volume of 1,495,747. Autolus Therapeutics has a twelve month low of $2.07 and a twelve month high of $7.45. The company’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $3.71. The firm has a market cap of $601.37 million, a price-to-earnings ratio of -1.87 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm earned ($0.26) earnings per share. Analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC grew its position in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after buying an additional 5,478,706 shares in the last quarter. Great Point Partners LLC raised its stake in shares of Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after buying an additional 2,275,000 shares in the last quarter. Armistice Capital LLC boosted its position in shares of Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Autolus Therapeutics by 74.5% during the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after purchasing an additional 1,080,897 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Wall Street Analysts Forecast Growth

AUTL has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.